Eric A Lefebvre

Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial

Wim A Wuyts, LISA H. LANCASTER, Toby M. Maher, Christopher J. Ryerson et autres

INTRODUCTION: in development for idiopathic pulmonary fibrosis (IPF). In the phase 2a study INTEGRIS-IPF study (NCT04396756), bexotegrast was well tolerated and showed antifibrotic activity. METHODS AND ANALYSIS: BEACON-IPF (NCT06097260) is a randomised, double-blind, placebo-controlled, dose-finding, operationally seamless, adaptive phase 2b/3 study evaluating …

be, us, ca, de, au, es, it, fr (code pays fourni par la source)

Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis

Gideon Morris Hirschfield, Kris V. Kowdley, Palak Jitendrakumar Trivedi, Bertus Eksteen et autres

Background & Aims Transforming growth factor-β signaling activated by α v β 6 and α v β 1 integrins drives liver fibrosis in primary sclerosing cholangitis (PSC). The aim of this study was to investigate the safety and exploratory pharmacodynamics of bexotegrast …

ca, us, gb, de, at (code pays fourni par la source)

Characterizing the antifibrotic activity of bexotegrast on pathologic cell populations in multiple ILD subtypes

Johanna R Schaub, Mahru C. An, Richard S. Ahn, Jennifer Yuzon et autres

Bexotegrast, a dual inhibitor of TGF-β-activating integrins αVβ6 and αVβ1 currently in late-stage clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), was previously shown to reduce profibrotic gene expression in pathologic cell populations of precision-cut lung slices (PCLS) generated from …

us (code pays fourni par la source)

Evaluation of the antifibrotic effect of a dual αvβ6/αvβ1 integrin inhibitor in a mouse model of rheumatoid arthritis-associated interstitial lung disease

Johanna R Schaub, Erine H. Budi, Eric A Lefebvre, Martin L. Decaris et autres

Bexotegrast, a dual inhibitor of TGF-β-activating integrins αVβ6 and αVβ1 currently in late-stage clinical development for the treatment of idiopathic pulmonary fibrosis, was previously shown to be antifibrotic in precision cut lung slices prepared from rheumatoid arthritis-associated interstitial lung disease (RA-ILD) patient …

us (code pays fourni par la source)

FP7 Bexotegrast improves markers and symptoms of cholestasis and stabilizes markers of liver fibrosis in participants with primary sclerosing cholangitis

Palak Jitendrakumar Trivedi, Kris V. Kowdley, Bertus Eksteen, Bilal Hameed et autres

gb, us, ca, de, at (code pays fourni par la source)

Experimental and numerical characterization of high-energy point-like x-ray sources for radiography applications at the LMJ-PETAL laser facility

Gaétan Sary, W. Cayzac, X. Vaisseau, X. Davoine et autres

We report on high-energy point-like x-ray backlighters generated with the short-pulse PETawatt Aquitaine Laser (PETAL) for the purpose of radiography experiments. 25-μm-diameter Ag wire backlighters were used to image 100-μm-thick Au slabs. Three backlighter configurations have been investigated in which the wire …

fr (code pays fourni par la source)

Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

Sydney B. Montesi, Gregory P. Cosgrove, Scott M. TURNER, Iris Yuwen Zhou et autres

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of type I collagen. 68Ga-CBP8, a type I collagen positron emission tomography probe, measures collagen accumulation and shows higher collagen deposition in patients with IPF. Bexotegrast (PLN-74809) is an oral, once-daily, …

us (code pays fourni par la source)

Role of kappa opioid and corticotrophin releasing factor 1 receptors in stress induced persistence of morphine seeking

F. Saulnier, D.R. Ulusoy, Eric A Lefebvre, Virginie Beray‐Berthat et autres

fr (code pays fourni par la source)

Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial

Joshua J. Mooney, Susan S. Jacobs, Eric A Lefebvre, Gregory P. Cosgrove et autres

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by dyspnea and loss of lung function. Transforming growth factor-β (TGF-β) activation mediated by αv integrins is central to the pathogenesis of IPF. Bexotegrast (PLN-74809) is an oral, once-daily, …

us, gb (code pays fourni par la source)

Post-hoc biomarker analysis in participants with IPF receiving bexotegrast over 12-weeks in INTEGRIS-IPF

Martin L. Decaris, Richard S. Ahn, Christopher N. Barnes, Eric A Lefebvre et autres

Rationale: Biomarkers of early therapeutic response are needed to inform drug development in idiopathic pulmonary fibrosis (IPF). Here we used proteomic screening to assess longitudinal changes in plasma protein levels in participants with IPF receiving bexotegrast, a dual-selective inhibitor of TGF-β-activating integrins …

us (code pays fourni par la source)

Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)

Gregory P. Cosgrove, Richard Pencek, Chris Barnes, Annie Clark et autres

Background: Bexotegrast (BEXO), an oral, once-daily, dual-selective inhibitor of integrins αvβ6 and αvβ1, has been studied in >700 participants from Phase 1 and Phase 2 trials in IPF and PSC Objectives: We report integrated safety and tolerability results from Phase 2 trials …

us (code pays fourni par la source)

Late Breaking Abstract - Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy

Sydney B. Montesi, Gregory P. Cosgrove, Scott M. TURNER, Iris Yuwen Zhou et autres

Background: Bexotegrast (BEXO, PLN-74809) is an oral, once-daily, dual-selective inhibitor of αvβ6 and αvβ1 integrins in development for treatment of IPF (BEACON-IPF; NCT06097260 ). Objectives: We report 12-week results in the first interventional Phase 2a study ( NCT05621252 ) evaluating type 1 …

us (code pays fourni par la source)